Blueprint Medicines Corp. (NASDAQ:BPMC)’s share price rose 2.6% during trading on Friday . The stock traded as high as $20.76 and last traded at $20.65, with a volume of 78,684 shares. The stock had previously closed at $20.13.

BPMC has been the topic of several recent analyst reports. Cowen and Company restated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, May 10th. Zacks Investment Research upgraded shares of Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Thursday, March 17th. Finally, Raymond James Financial Inc. initiated coverage on shares of Blueprint Medicines Corp. in a report on Friday, May 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Blueprint Medicines Corp. currently has an average rating of “Buy” and an average price target of $28.50.

The firm has a 50 day moving average of $19.72 and a 200 day moving average of $18.14. The firm’s market cap is $560.46 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last released its earnings results on Tuesday, May 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.13. The company earned $6.90 million during the quarter, compared to analyst estimates of $3.24 million. Blueprint Medicines Corp.’s revenue was up 961.5% compared to the same quarter last year. On average, analysts predict that Blueprint Medicines Corp. will post ($3.10) earnings per share for the current year.

In related news, CEO Jeffrey W. Albers sold 17,000 shares of the firm’s stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $20.03, for a total value of $340,510.00. Following the sale, the chief executive officer now directly owns 92,486 shares of the company’s stock, valued at $1,852,494.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.